<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01400854</url>
  </required_header>
  <id_info>
    <org_study_id>C25608/5008</org_study_id>
    <nct_id>NCT01400854</nct_id>
  </id_info>
  <brief_title>Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability</brief_title>
  <acronym>ERKENTNIS</acronym>
  <official_title>ERKENTNIS: Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this non-interventional study is to investigate the tolerability of Effentora® in
      cancer pain patients with breakthrough pain under real-life conditions in clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to the effectiveness of Effentora® therapy, safety, general feasibility and the
      impact of therapy on the patients' quality of life are of interest.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pain relief</measure>
    <time_frame>4 weeks</time_frame>
    <description>to show adequate pain relief within 10 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>document the tolerability of Effentora®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of breakthrough pain</measure>
    <time_frame>4 weeks</time_frame>
    <description>pursue the possible changes in the history of breakthrough pain during treatment with Effentora</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of specific triggers for breakthrough pain</measure>
    <time_frame>4 weeks</time_frame>
    <description>to investigate the presence of specific triggers (directly or indirectly) with breakthrough pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>4 weeks</time_frame>
    <description>to document the impact of breakthrough pain in different areas of patients' lives and their changes during treatment with Effentora®</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Effentora®</arm_group_label>
    <description>Single group prospective treatment cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effentora®</intervention_name>
    <description>prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration</description>
    <arm_group_label>Effentora®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult cancer patients (in- or out-patients) that are suffering from breakthrough pain
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  decision to start treatment with Effentora

          -  prescription in accordance with Summary of Product Characteristics (SmPC)

          -  personally signed and dated Informed Consent document

        Exclusion Criteria:

          -  any subject considered unsuitable according to SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Department</last_name>
    <role>Study Director</role>
    <affiliation>Cephalon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cephalon GmbH</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>October 23, 2012</last_update_submitted>
  <last_update_submitted_qc>October 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breakthrough cancer pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

